食管癌放化疗期间严重淋巴细胞减少:质子束治疗对比调强放射治疗随机2B期试验的综合分析
该研究基于一项单中心、开放标签、非盲法2期随机试验(NCT01512589),比较食管癌放化疗患者接受质子束治疗与调强光子放疗后4级淋巴细胞减少的发生率。105例可评估患者中44例(42%)发生4级淋巴细胞减少,中位发生时间为同步放化疗开始后28天;诱导化疗、基线绝对淋巴细胞计数、放疗方式和计划治疗体积与4级淋巴细胞减少显著相关。多因素分类分析将患者分为5个亚组,4级淋巴细胞减少发生率分别为0%、14%、35%、70%和100%;质子束治疗优于调强放疗的获益在基线绝对淋巴细胞计数中等且计划治疗体积较大的患者中最明显(P = .011)。
要点
- 105例可评估患者中44例(42%)发生4级淋巴细胞减少,中位时间为同步放化疗开始后28天。
- 诱导化疗(P = .003)、基线绝对淋巴细胞计数(P < .001)、放疗方式(P = .002)和计划治疗体积(P = .033)与4级淋巴细胞减少显著相关。
- 质子束治疗较调强放疗的获益在基线绝对淋巴细胞计数中等且计划治疗体积较大的患者中最明显(P = .011)。
核心结论
- 这是首个前瞻性证据表明质子束治疗通过限制剂量散射显著降低4级淋巴细胞减少发生率,尤其是在中等风险患者中。
- 质子束治疗这种免疫保护效应的意义,特别是在标准辅助免疫治疗背景下,需要在当前3期随机试验中进一步检验。
研究设计与样本
- 2012年4月至2019年3月在德克萨斯大学MD安德森癌症中心开展的单中心、开放标签、非盲法2期随机试验(NCT01512589)。
- 患者随机分配至调强放疗或质子束治疗,行根治性或术前放化疗。
- 本分析为该随机试验的二次分析,以常见不良事件评价标准5.0版定义同步放化疗期间4级淋巴细胞减少。
- 105例患者可评估分析。
主要发现
- 105例可评估患者中44例(42%)发生4级淋巴细胞减少,中位时间为同步放化疗开始后28天。
- 诱导化疗(P = .003)、基线绝对淋巴细胞计数(P < .001)、放疗方式(P = .002)和计划治疗体积(P = .033)与4级淋巴细胞减少显著相关。
- 多因素分类分析将患者分为5个亚组,4级淋巴细胞减少发生率分别为0%、14%、35%、70%和100%。
- 质子束治疗优于调强放疗的获益在基线绝对淋巴细胞计数中等且计划治疗体积较大的患者中最明显(P = .011)。
局限性
- 原文结论指出,质子束治疗免疫保护效应的意义需要在当前3期随机试验中进一步检验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Lymphocytes play an important role in antitumor immunity; however, they are also especially vulnerable to depletion during chemoradiation therapy (CRT). The purpose of this study was to compare the incidence of grade 4 lymphopenia (G4L) between proton beam therapy (PBT) and intensity modulated photon radiation therapy (IMRT) in patients with esophageal cancer treated with CRT in a completed randomized trial and to ascertain patient heterogeneity to G4L risk based on treatment and established prognostic factors. METHODS AND MATERIALS: Between April 2012 and March 2019, a single-institution, open-label, nonblinded, phase 2 randomized trial (NCT01512589) was conducted at the University of Texas MD Anderson Cancer Center. Patients were randomly assigned to IMRT or PBT, either definitively or preoperatively. This secondary analysis of the randomized trial was G4L during concurrent CRT according to Common Terminology Criteria for Adverse Events version 5.0. RESULTS: Among 105 patients evaluable for analysis, 44 patients (42%) experienced G4L at a median of 28 days after the start date of concurrent CRT. Induction chemotherapy (P = .003), baseline absolute lymphocyte count (P < .001), radiation therapy modality (P = .002), and planning treatment volume (P = .033) were found to be significantly associated with G4L. Multivariate classification analysis partitioned patients into 5 subgroups for whom the incidence of G4L was observed in 0%, 14%, 35%, 70%, and 100% of patients. The benefit of PBT over IMRT was most pronounced in patients with an intermediate baseline absolute lymphocyte count and large planning treatment volume (P = .011). CONCLUSIONS: This is the first prospective evidence that limiting dose scatter by PBT significantly reduced the incidence of G4L, especially in the intermediate-risk patients. The implication of this immune-sparing effect of PBT, especially in the context of standard adjuvant immunotherapy, needs further examination in the current phase 3 randomized trials.
引用
- Wang X, van Rossum PSN, Chu Y, et al. Severe Lymphopenia During Chemoradiation Therapy for Esophageal Cancer: Comprehensive Analysis of Randomized Phase 2B Trial of Proton Beam Therapy Versus Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2023. PMID: 37652304. doi:10.1016/j.ijrobp.2023.08.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。